With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.120737-59-9,tert-Butyl 3-methylpiperazine-1-carboxylate,as a common compound, the synthetic route is as follows.
Methyl-bromoacetate (3.06g, 20.0 mmol) was added to a stirred solution of 4-Boc-2-methyl- piperazine (2. [0G,] 10.0 mmol), sodium iodide [(0.] [LG.)] and N, N-diisopropylethylamine (3.48 ml, 20 mmol) in DCM (50ml) at ambient temperature under nitrogen. After stirring for 16h the reaction mixture was washed with water [(30ML),] brine [(30ML),] dried and evaporated to dryness under reduced pressure. The residue was purified by chromatography on silica, eluting with 0-8percent [MEOH/DCM] to give 68 as a yellow oil (2.7g). MS-ESI: 273 (M++H). [H NMR (CDC13) 1. 05] (d, 3H), 1.47 (s, 9H), 2.50-2. 85 (m, 4H), 3.03-3. 13 (m, 1H), 3.34 (d, 1H), 3.44 (d, [1H),] 3.70 (s, 3H), 3.71-3. 82 (m, 2H)., 120737-59-9
As the paragraph descriping shows that 120737-59-9 is playing an increasingly important role.
Reference£º
Patent; ASTRAZENECA AB; ASTRAZENECA UK LIMITED; WO2004/18480; (2004); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics